secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001193125-24-238564
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath reports preliminary Q3 revenue $11.2M; HEPZATO KIT sales trigger $25M warrant exercise
--------------------------------------------------------------------------------

- Preliminary Q3 2024 revenue of $11.2M, including $10M U.S. sales from HEPZATO KIT.
- Announcement of $10M U.S. quarterly revenue triggers exercise of Tranche B warrants from March 2023 PIPE.
- Warrant holders have 21 days to exercise at $6/share for aggregate $25M.
- Proceeds to support HEPZATO KIT commercial launch and fund new clinical trials for expanded indications.
- Final Q3 results and business update scheduled for investor call on November 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/0001193125-24-238564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/d837829d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer